U.S., June 5 -- ClinicalTrials.gov registry received information related to the study (NCT07627984) titled 'Cerebral Embolic Protection Device During TAVR' on May 22.
Brief Summary: To evaluate the safety and effectiveness of the Cerebral Protection System (model CEP016F, Shanghai Shenqi Medical Technology Co., Ltd.) for capturing and removing thrombotic and tissue debris during transcatheter aortic valve replacement (TAVR).
Study Start Date: Sept. 20, 2023
Study Type: INTERVENTIONAL
Condition:
Cerebral Embolicprotection Device
TAVR
Intervention:
DEVICE: Cerebral embolic protection device
The cerebral embolic protection device is a percutaneously delivered dual-filter protection device designed to capture and remove dislodged debris...